EUROBAK AWARD
Necessary help for patients
A new type of coronavirus , which is raging in the world and here in Kazakhstan , has overshadowed a number of other diseases , although patients suffering from various ailments still need help and support . In this difficult time , the leaders of the world pharmaceutical industry are not only working on the creation of vaccines and drugs for the new virus , but also showing their social responsibility to society .
So in Kazakhstan , schools have been organized for patients with Hodgkin ’ s lymphoma , inflammatory bowel diseases ( IBD ), mucopolysaccharidosis type II ( MPS II ), and hemophilia . Through regular online seminars and trainings , patients receive important practical information from healthcare professionals , as well as share the problems they face in relation to diseases . These patient schools not only solve the problem of lack of information for patients , but also help them overcome inevitable psychological problems .
The biopharmaceutical company Takeda organized and initiated the schools in participation with the following public funds : Help Today , the fund for patients with mucopolysaccharidosis and rare diseases called Zhana Omir , the fund for assistance to persons with IBD called KazIOR , Together Against Cancer , the Kazakhstan Association of Disabled People with Hemophilia Fund , as well as Kazakhstan healthcare professionals .
At the same time , in the context of the COVID-19 pandemic in Kazakhstan , there is a shortage of infusion systems for the planned administration of drugs to patients with chronic diseases , since special attention is paid to the functioning of the intensive care and intensive care units , where these systems are used for severe patients . In particular , patients with a rare genetic disease – Hunter syndrome , also known as type II mucopolysaccharidosis ( MPS II ) – have difficulties with the proper administration of enzyme replacement therapy ( ERT ), which can lead to an increase in adverse reactions and a decrease in adherence to therapy .
Based on requests from patients with MPS II from different regions of Kazakhstan , Takeda donated to the Help Today Fund , which made it possible to cover the needs of all patients needing infusion systems and ensure the continuity of enzyme replacement therapy .
As a result of the additional donation , all patients with Hunter syndrome in need received the necessary equipment to continuously treat their chronic disease , even in the face of a pandemic . Ensuring proper administration of enzyme replacement therapy for patients with Hunter syndrome is critical to prevent complications and improve quality of life .
78 world monitor